INTRODUCTION
============

Adenovirus is a well-known pathogen of mild upper respiratory tract illness which is usually self-limited. In pediatric patients, adenovirus pneumonia can present with the features of bacterial pneumonia ([@B1]). Many cases of fatal adenovirus respiratory infection in immune-suppressed adults have been described in the literature. Because humoral and cellular immunity are generally important in overcoming viral infection, life-threatening adenovirus pneumonia in patients with defective or deficient T-cell immunity, such as those with bone marrow or solid organ transplant, malignant neoplasm, or AIDS, has been reported ([@B2][@B3][@B4][@B5]). However, there have been a few cases of adenovirus pneumonia in immunocompetent adults. Historically, epidemics and outbreaks of adenovirus pneumonia in military recruits and health care facilities have been described ([@B6][@B7][@B8][@B9]). These cases have raised concerns about adenovirus infection in the general population, but there is still limited information on the condition.

We had encountered several patients in our clinical practice with adenovirus pneumonia that rapidly progressed to respiratory failure, and we thought that it was worthwhile to report the clinical and radiological spectra of adenovirus pneumonia in civilian adults. Furthermore, if any clinico-radiological factors appeared to foreshadow the development of acute respiratory distress syndrome (ARDS), aggressive treatment and careful follow-up evaluation can be prepared in advance. Thus, the aim of our study was to identify the incidence, clinical features, survival outcome, and radiological findings of adenovirus pneumonia acquired in the community. We also compared clinico-radiological factors between patients with and without ARDS in order to determine possible predictors for patients who might develop respiratory failure.

MATERIALS AND METHODS
=====================

The institutional review board approved our retrospective study, and written informed consent was waived for the use of patients\' medical and imaging data. All of the patients\' information was anonymized prior to the analysis.

Study Population
----------------

We identified 19 adult patients (14 males and 5 females; median age, 38 years) who were diagnosed with adenovirus pneumonia between March 2003 and April 2015 in a single tertiary-referral hospital. All patients underwent Gram stains, bacterial and fungal cultures of blood and urine. Sputum was stained and cultured for bacteria, mycobacteria, and fungi. Specimens from patients who underwent bronchoscopy with the collection of bronchoalveolar lavage (BAL) fluid or lung biopsy, as well as those who underwent surgical biopsy, were stained and cultured for bacteria, mycobacteria, and fungi. In addition, polymerase chain reaction (PCR) analysis for BAL specimens and nasal or throat swabs were performed to detect viral organisms. Patients in whom other infectious organisms were identified in the sputum, blood, urine, nasal and throat swabs, BAL fluid, or lung specimen within four weeks of adenovirus identification were regarded to have a concurrent infection and were excluded from this study. Finally, 19 patients confirmed to have only adenovirus pneumonia were included in this study; these patients included the five patients whose imaging features were published in our previous study ([@B10]).

All data including age, sex, premorbid conditions, symptoms, laboratory and pathological findings, clinical course, treatment, and survival outcome were drawn from patient electronic medical records. Patients were regarded as having ARDS when they satisfied the American-European Consensus Conference definition for the condition: acute onset of respiratory failure, bilateral infiltrates on chest radiograph, hypoxemia as defined by a ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2 ratio) ≤ 200 mm Hg, and no evidence of left atrial hypertension or pulmonary capillary pressure \< 18 mm Hg (if measured) to rule out cardiogenic edema ([@B11]).

Diagnosis of Adenovirus Pneumonia
---------------------------------

Diagnosis was confirmed in five patients based on positive viral culture for adenovirus in BAL fluid. Diagnosis via lung biopsy specimens obtained by video-assisted thoracoscopic surgery (n = 4) or transbronchial lung biopsy (n = 1) was made in another five patients. The specimens were evaluated using hematoxylin and eosin immunohistochemical staining ([@B10][@B12]). In nine patients, BAL fluid was analyzed using the one-step multiplex realtime AdvanSure RV real-time PCR kit (LG Life Sciences, Seoul, Korea) or conventional multiplex reverse transcription PCR (RT-PCR) assay (Seeplex RV12 Detection Kit; Seegene, Seoul, Korea) ([@B13][@B14]).

Image Acquisition
-----------------

Initial chest radiographs and computed tomography (CT) scans were acquired after an average of 4.4 days (range, 0 to 15 days) or 6.1 days (range, 2 to 15 days) from the commencement of symptoms or signs, respectively. The mean time interval between radiologic examination and pathological or microbiological diagnosis was 9.6 days (range, 1--72 days). In one patient whose interval from initial imaging study to pathological diagnosis was 72 days, confirmative diagnosis of adenovirus pneumonia was delayed due to antibiotics treatment showing gradual deterioration of the disease.

Posterior-anterior chest radiographs were obtained with a computed radiography system (FCR 9501; Fuji, Tokyo, Japan) or digital radiography system (Revolution XQi ADS_28.4; GE Medical Systems, Milwaukee, WI, USA) with operating parameters of 70--120 kVp and 2--3 mAs. Serial chest radiographs were acquired for all patients during hospitalization in order to assess the progression of disease. CT studies were performed using various helical CT scanners (Hi Speed Advantage, Light Speed QXi, Light Speed Ultra, Light Speed VCT and Discovery CT750 HD, GE Healthcare, Chalfont St Giles, England; Brilliance 40, Philips, Best, the Netherlands; Aquilion, Toshiba, Tokyo, Japan). CT scans (114--210 mA, 120 kVp, beam width of 10--20 mm, beam pitch of 1.375--1.5) were performed from the lung apices to the level of the middle portions of both kidneys. Intravenous contrast medium injection was used in approximately half of the patients (10 patients), with 1.5 mL/kg (body weight) of Iomeron 300 (iomeprol, 300 mg iodine/mL; Bracco, Milan, Italy) injected at an infusion rate of 3 mL/s using a power injector (MCT Plus; Medrad, Pittsburgh, PA, USA). The imaging data were reconstructed with section thicknesses of 2.5--5 mm using a bone algorithm. The reconstructed images were then interfaced directly to a picture archiving and communication system (Centricity 3.0; GE Healthcare, Mt. Prospect, IL, USA), which displayed all image data on two monitors (1536 × 2048 matrix, 8-bit viewable gray scale, and 60-ft-lambert luminescence). Both mediastinal (width, 400 HU; level, 20 HU) and lung (width, 1500 HU; level, -700 HU) window images were viewed on these monitors.

Image Analysis
--------------

Two chest radiologists (MJC and MJJ, with five and 22 years of experience in chest imaging interpretation, respectively) assessed chest radiographs and CT images; decisions were reached by consensus. The abnormalities on initial chest radiographs were assessed as focal opacity or multifocal or diffuse opacity ([@B15]). Parenchymal opacity was defined as an area that appears denser than the surrounding lung tissue without a discrete border. The pattern of the disease course was also identified from sequential chest radiographs as described by Wong et al. ([@B16]) and Das et al. ([@B17]), where type 1 was radiographic improvement, type 2 was radiographic deterioration by one peak level followed by improvement, type 3 was fluctuating radiographic changes with at least two peaks, and type 4 was progressive radiographic deterioration. Peak level was defined as overall lung parenchymal involvement greater than 25% of the initial extent on radiography.

On CT, the patterns of parenchymal abnormalities were subdivided into areas of ground-glass opacity (GGO), consolidation, and micronodules (\< 5 mm in diameter). GGO was defined as an area of hazy increased lung opacity, within which margins of pulmonary vessels were indistinct. Consolidation was defined as a homogeneous increase in pulmonary parenchymal opacity that obscured the margins of vessels and airway walls ([@B18]). The presence of interlobular septal thickening or pleural effusion was also recorded, and the laterality (unilateral vs. bilateral) of the lesions was evaluated. Septal thickening was defined as abnormal widening of an interlobular septum or septa ([@B18]). In terms of anatomic location, the distribution of parenchymal abnormalities was classified as central, peripheral, or mixed in the axial plane and upper, lower, or random in the longitudinal plane. The outer third of the lung was defined as peripheral, and the inner two-thirds of the lung were defined as central. The lesions were regarded as distributed in the upper lung zone when they were located above the hilum, in the lower lung zone when they were located below the hilum, or random when the distribution could not be determined. For the acquisition of CT scores, the lung was also divided into upper (above the carina), middle (below the carina and up to the inferior pulmonary vein), and lower (below the inferior pulmonary vein) zones. The involvement of pneumonia within each lung zone was evaluated by scoring each zone from 0 (normal) to 4, with 4 corresponding to nearly total involvement of the lung parenchyma. Total CT scores ranged from 0 to 24 when combined for all six zones ([@B17][@B19]).

Statistical Analysis
--------------------

Differences in the clinico-radiological characteristics of the patients who eventually developed ARDS (ARDS group) and those who did not (non-ARDS group) were assessed by using chi-square test, Fisher\'s exact test, or Student\'s *t* test. Statistical analyses were performed with SPSS software (version 19.0; SPSS Inc., Chicago, IL, USA). A *p* value less than 0.05 was considered to indicate a significant difference.

RESULTS
=======

Demographics and Clinical Characteristics
-----------------------------------------

Detailed patient characteristics are shown in [Table 1](#T1){ref-type="table"}. Among the 19 patients with adenovirus pneumonia, nine were immunocompromised due to underlying comorbid conditions, such as acute myeloid leukemia (n = 4), non-Hodgkin\'s lymphoma (n = 1), multiple myeloma (n = 1), lung adenocarcinoma (n = 1), history of liver transplantation for hepatocellular carcinoma (n = 1), and diabetes mellitus in conjunction with chronic obstructive pulmonary disease and ischemic cardiomyopathy (n = 1). In contrast, 10 patients were immunocompetent without underlying disease.

Most patients had upper respiratory symptoms such as dyspnea, cough, sputum, fever, and chills, as shown in [Table 1](#T1){ref-type="table"}. Twelve of 19 patients (63%) subsequently progressed to ARDS, six (32%) of whom eventually died. The average time of progression from commencement of symptoms or signs to ARDS was 9.6 days, indicating relatively rapid deterioration. Fifteen patients received antiviral therapy, including ganciclovir (n = 1), ribavirin (n = 3), or cidofovir (n = 11).

Radiological Findings
---------------------

Initial chest radiographs of two patients (11%) were normal, whereas 17 patients had abnormal chest radiographs that showed multifocal or diffuse opacity (n = 8, [Fig. 1](#F1){ref-type="fig"}), or focal opacity (n = 9, [Figs. 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}). In terms of the disease course identified from serial chest radiographs, two showed gradual improvement (type 1, [Fig. 2](#F2){ref-type="fig"}), nine showed initial radiographic deterioration by one peak level followed by improvement (type 2), two showed radiographic fluctuations with at least two peaks (type 3), and six patients showed progressive radiographic deterioration (type 4, [Figs. 1](#F1){ref-type="fig"}, [3](#F3){ref-type="fig"}).

Patterns and distribution of CT findings are summarized in [Table 2](#T2){ref-type="table"}. The most frequent CT appearance was GGO, which was seen in all patients (n = 19), combined with other patterns such as consolidation (n = 14) and micronodules (n = 3). Parenchymal abnormalities were distributed bilaterally in 17 patients ([Figs. 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}), whereas unilateral involvement was seen in two patients ([Fig. 3](#F3){ref-type="fig"}). Interlobular septal thickening was demonstrated in 12 patients, and pleural effusion was present in 11 patients. The average number of lobes involved was 4.2 ± 1.4 (range, 1 to 5). Pulmonary abnormalities showed upper lung zone predominance in four patients (21%) and lower lung zone predominance in six patients (32%). However, nine patients (47%) showed random parenchymal involvement without zonal predominance. In terms of axial distribution, most of the cases (79%) showed mixed central and peripheral involvement.

Comparisons between ARDS and Non-ARDS Groups
--------------------------------------------

[Table 3](#T3){ref-type="table"} shows the comparison between the ARDS and non-ARDS groups according to clinical and radiological findings. No significant differences between the groups were identified for the clinical variables of patient age (*p* = 0.651), sex (*p* = 0.998), or presence of premorbid conditions (*p* = 0.650). Regarding the radiological findings, there was no significant difference in initial radiograph findings (*p* = 0.813), but the radiographic pattern of disease course differed significantly between the ARDS and non-ARDS groups (*p* = 0.048). In the non-ARDS group, types 1 and 2 accounted for more than 85% of patients, and no one was classified as type 4. In contrast, half of the patients in the ARDS group showed progressive deterioration of chest radiographs and were classified as type 4. Among the CT findings, the presence of pleural effusion and total CT scores differed significantly (*p* = 0.010 and *p* = 0.007, respectively) between the two groups. Patients who progressed to ARDS showed higher total CT scores and a higher probability of pleural effusion. Other CT features, such as laterality (*p* = 0.998), presence of consolidation (*p* = 0.305) and micronodules (*p* = 0.997), inter- or intralobular septal thickening (*p* = 0.656), and number of involved lobes (*p* = 0.973) did not differ significantly between the ARDS and non-ARDS groups.

DISCUSSION
==========

In our study, progression to respiratory failure was unpredictable, showing relatively high rates (12 of 19 patients, 63%) and rapid deterioration. There were no significant differences in baseline clinical characteristics between the ARDS and non-ARDS groups. This result is different from previous reports indicating that geriatric immunocompromised patients are more prone to pneumonia and to developing ARDS than are young immunocompetent patients ([@B20][@B21][@B22]). Our study suggests that, if adenovirus infection manifests as airspace lesions on chest radiograph or CT, aggressive treatment and careful follow-up should be carried out, regardless of patient age and premorbid conditions; patients with these conditions showed a rapid progression of the disease to ARDS.

Our study also demonstrated that the disease extent seen on chest CT, which was defined by total CT score and the presence of pleural effusion significantly differed between the ARDS and non-ARDS groups ([Fig. 1](#F1){ref-type="fig"}). In addition, the patients in the ARDS group showed progressive deterioration on sequential radiographs, rather than fluctuations or improvement. This result is consistent with previous reports regarding prognoses of other viral pneumonias such as H1N1, severe acute respiratory syndrome, and Middle East respiratory syndrome ([@B16][@B17][@B23]). Close imaging follow-up for the evaluation of disease progression should be a requisite in managing patients with adenovirus pneumonia.

One can argue that the rate of respiratory failure in adenovirus pneumonia might have been overestimated in our study, considering the way that adenovirus pneumonia was confirmed. The effort for confirmatory diagnosis was usually made when the results of laboratory evaluations, including the staining and culture of blood, urine, and sputum, were negative, and the response to empirical antibiotic therapy was unsatisfactory. Thus, the diagnosis might have been delayed, missing the important opportunity for timely treatment. In addition, our institution is a tertiary referral hospital in Seoul; thus, the rates of ARDS and mortality could be further exaggerated. We admit that the rates of ARDS and mortality of adenovirus pneumonia in our study might not be applicable to those of adenovirus pneumonia in the general community. Nevertheless, we think that our results are meaningful with respect to emphasizing the severity of adenovirus pneumonia.

It is curious that adenovirus pneumonia developed into ARDS with such a high percentage in our study. It is known that adenovirus causes cytolysis, which accounts for tissue damage, and damaged pulmonary capillaries can contribute to respiratory failure ([@B24]). Another possible explanation is the unregulated complement activation, producing C5a and resulting in activation of phagocytic cells, generation of oxidants, release of histones, and, eventually, a cytokine storm ([@B25][@B26]). Many previous cases of respiratory failure resulting from influenza A viruses H1N1, H5N1, and H7N9, severe acute respiratory syndrome coronavirus, and Middle East respiratory syndrome coronavirus pneumonia were associated with cytokine storms ([@B27]). Similar to these highly pathogenic viruses which have been severe threats to public health, adenovirus might have triggered cytokine storms in patients who progressed to ARDS. However, it is still difficult to explain why some individuals are susceptible to systemic inflammation, whereas others are resistant to it. Further studies should be performed to identify the viral determinants and genetic factors associated with ARDS, and to better understand the pathophysiology of adenovirus infection.

In terms of the radiological findings of adenovirus pneumonia, the CT features were so diverse that it was difficult to define specific findings for adenovirus pneumonia. Although the most common CT feature was bilateral ground-glass opacities, the findings were variable, from unilateral lobar consolidation to clustered micronodules. With regard to the initial chest radiographic findings, two patients (11%) were normal, while focal opacity was noted in nine patients (47%). Despite the well-known imaging features of viral pneumonia, which causes diffuse and bilateral interstitial involvement ([@B28]), two patients in our study presented with unilateral consolidation and GGO with or without pleural effusion. Features of focal opacity on chest radiograph and unilateral dense consolidation on CT were likely to be interpreted as community-acquired pneumonia. In fact, there have been several reports describing adenovirus pneumonias that have presented with unilateral lobar infiltrates ([@B6][@B8][@B20]). Thus, we should not discard the possibility of adenoviral pneumonia in patients suspected of having an acute lower respiratory tract infection with unilateral airspace lesion, especially when response to antibiotics was ineffective, and sputum Gram stain and culture were negative for bacterial infection. Every effort should be made to achieve a confirmative diagnosis and timely treatment in such cases.

There are limitations to our study. First, our study was retrospective in nature and thus had a selection bias. Patients with adenovirus pneumonia who had severe respiratory symptoms or abnormal radiologic findings might have been selectively included. Second, we did not perform a serotype analysis of adenovirus. To date, more than 52 serotypes of adenovirus have been recognized and are known to show different biological properties ([@B29]). Further work needs to be performed investigating the virulent strains of adenovirus, particularly with regard to radiologic appearance, disease extent, and severity. Third, the time to CT acquisition from symptom onset was heterogeneous, ranging from two to 15 days. CT scans from the ARDS group might have progressed from an initially mild disease to showing a relatively large extent of involvement. Fourth, we simplified the chest radiographic abnormality as focal, multifocal, and diffuse opacity without assessing other findings such as interstitial opacities. However, we were more focused on the disease extent and sequential radiographic changes rather than detailed radiographic findings. Fifth, our study only included patients confirmed to have adenovirus pneumonia and did not include a comparison group. Sixth, the diagnosis of adenovirus pneumonia was made using various methods. Lastly, the number of cases in the present study is small, and a large-scale prospective study is needed. In addition, comparison of clinico-radiological features between immunocompromised and immunocompetent patients with adenovirus pneumonia would also have clinical implications toward understanding the clinical course of the disease.

In conclusion, our study demonstrates that adenovirus pneumonia is associated with high rates of ARDS and mortality in the single tertiary care setting. Adenovirus pneumonia usually manifests as multifocal or diffuse opacity on chest radiographs, and bilateral GGO and consolidation with or without pleural effusion on CT. However, we should remember that adenovirus pneumonia can also present as focal opacity with unilateral airspace lesions. Patients with adenovirus pneumonia demonstrate subsequent rapid deterioration to ARDS regardless of age and premorbid conditions; thus, aggressive treatment and careful follow-up are mandatory. In particular, patients who have progressed to ARDS are prone to show a large disease extent and high probability of pleural effusion on CT, supporting the importance of intensive imaging follow-up in patients suffering from adenovirus pneumonia.

![20-year-old immunocompetent man complaining of fever, dyspnea, productive cough, and sputum.\
He visited our hospital on 10th day from onset of his symptoms, which were abruptly aggravated two days prior. **A.** Chest radiograph demonstrates multifocal or diffuse opacity. **B.** Chest CT scan obtained on same day demonstrates extensive airspace lesions in both lungs, with bilateral pleural effusions. Total CT score was 13. Culture of BAL fluid helped confirm adenovirus pneumonia. On next day, patient was transferred to intensive care unit, and he eventually expired on 21st day of hospitalization. BAL = bronchoalveolar lavage, CT = computed tomography](kjr-17-940-g001){#F1}

![38-year-old woman with acute myelogenous leukemia visited our institution for aggravated fever, cough, sputum, and dyspnea for four days.\
**A.** Chest radiograph at admission demonstrates subtle focal opacity in right upper lung zone (white arrow). **B, C.** Chest CT scans obtained on same day demonstrate patchy peribronchial ground-glass opacity in both lungs (black arrows). Total CT score was 3. Culture and RT-PCR of BAL fluid confirmed adenovirus pneumonia. **D.** Follow-up chest radiograph obtained after two weeks of treatment with cidofovir demonstrates disappearance of focal opacity in right upper lung zone, suggesting type 1 disease pattern. BAL = bronchoalveolar lavage, CT = computed tomography, RT-PCR = reverse transcription polymerase chain reaction](kjr-17-940-g002){#F2}

![20-year-old immunocompetent man suffering from acute fever and dyspnea.\
**A.** Chest radiograph obtained on fifth day of illness demonstrates focal opacity in left lower lobe (arrow). **B, C.** Chest CT scans demonstrate dense consolidation and ground-glass opacity in left lower lobe (arrow). Small left pleural effusion is indicated by open arrow. Total CT score was 7. **D.** Chest radiograph obtained on seventh day of illness demonstrates increased amount of left pleural effusion and bilateral multifocal areas of parenchymal opacity. **E.** Progressive diffuse opacity in both lungs and bilateral pleural effusions are shown on follow-up radiograph taken on 13th day, suggesting ARDS and type 4 disease pattern. Patient expired on 16th day of illness. ARDS = acute respiratory distress syndrome, CT = computed tomography](kjr-17-940-g003){#F3}

###### Clinical Features and Radiological Findings of 19 Patients with Adenovirus Pneumonia

![](kjr-17-940-i001)

  Patient No.   Age (yr)/Sex   Premorbid Condition   Initial Presentation     Disease Course on X-ray   CT Score   Diagnosis             Progression to ARDS   Time to Progression to ARDS   Antiviral Treatment   Pneumonia-Related Outcome
  ------------- -------------- --------------------- ------------------------ ------------------------- ---------- --------------------- --------------------- ----------------------------- --------------------- ---------------------------
  1             67/M           Lung Cancer           Dyspnea, C/S             Type 2                    15         BAL culture           Y                     3rd day of illness            No                    
  2             47/M           AML                   Fever, chills, C/S       Type 4                    6          TBLB, BAL culture     Y                     20th day of illness           Cidofovir             Expired
  3             36/F           AML                   Dyspnea, cough, BTS      Type 3                    3          VATS                  N                     N/A                           Ribavirin             
  4             75/F           No                    Dyspnea, fever           Type 4                    21         VATS                  Y                     14th day of illness           Ganciclovir           Expired
  5             35/F           NHL                   Fever, chills, C/S       Type 4                    10         VATS                  Y                     4th day of illness            Ribavirin             Expired
  6             67/F           No                    Dyspnea                  Type 2                    12         VATS                  Y                     11th day of illness           Ribavirin             
  7             53/M           AML                   Fever, chills            Type 2                    11         BAL culture           N                     N/A                           Cidofovir             
  8             55/M           MM                    Fever, chills            Type 2                    7          BAL culture           N                     N/A                           No                    
  9             20/M           No                    Dyspnea, fever, sputum   Type 4                    12         BAL culture           Y                     12th day of illness           Cidofovir             Expired
  10            38/F           AML                   Fever, dyspnea, C/S      Type 1                    3          RT-PCR, BAL culture   N                     N/A                           Cidofovir             
  11            20/M           No                    Fever, dyspnea, C/S      Type 1                    13         RT-PCR                N                     N/A                           No                    
  12            42/M           Liver transplant      Fever, chills            Type 4                    20         Real-time PCR         Y                     5th day of illness            Cidofovir             Expired
  13            23/M           No                    Fever, chills, C/S       Type 2                    15         Real-time PCR         Y                     18th day of illness           Cidofovir             
  14            20/M           No                    Fever, dyspnea           Type 4                    7          Real-time PCR         Y                     9th day of illness            Cidofovir             Expired
  15            28/M           No                    Fever, chills, myalgia   Type 2                    13         Real-time PCR         Y                     7th day of illness            Cidofovir             
  16            19/M           No                    Fever, chills, C/S       Type 2                    3          Real-time PCR         N                     N/A                           Cidofovir             
  17            20/M           No                    Fever, dyspnea           Type 2                    11         Real-time PCR         Y                     7th day of illness            Cidofovir             
  18            51/M           No                    Fever, chills, C/S       Type 2                    5          Real-time PCR         N                     N/A                           No                    
  19            75/M           DM, COPD, ICMP        Dyspnea, C/S             Type 3                    12         BAL culture           Y                     12th day of illness           Cidofovir             

AML = acute myeloid leukemia, ARDS = acute respiratory distress syndrome, BAL = bronchoalveolar lavage, BTS = blood tinged sputum, COPD = chronic obstructive pulmonary disease, C/S = cough and sputum, DM = diabetes mellitus, ICMP = ischemic cardiomyopathy, MM = multiple myeloma, N/A = not applicable, NHL = non-Hodgkin lymphoma, PCR = polymerase chain reaction, RT-PCR = reverse transcription PCR, TBLB = transbronchial lung biopsy, VATS = video-assisted thoracoscopic surgery

###### Patterns and Distribution of CT Findings in 19 Patients with Adenovirus Pneumonia
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  CT Pattern                                              Laterality   Longitudinal Zone   Axial Distribution                   
  ------------------------------------------------------- ------------ ------------------- -------------------- --- --- --- --- ----
  Ground-glass opacity (n = 19 \[100%\])                  2            17                  4                    6   9   1   3   15
  Consolidation (n = 14 \[74%\])                          2            12                  2                    6   6   0   3   11
  Micronodules (n = 3 \[15%\])                            0            3                   1                    0   2   1   0   2
  Inter/intralobular septal thickening (n = 12 \[63%\])   1            11                  2                    4   6   1   0   11

CT = computed tomography

###### Comparison of ARDS and Non-ARDS Groups according to Clinical and Radiological Factors
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  Characteristics                             All (n = 19)     ARDS Group (n = 12)   Non-ARDS Group (n = 7)   *P*
  ------------------------------------------- ---------------- --------------------- ------------------------ -------
  Age (yr)                                    41.6 ± 19.1      43.3 ± 22.3           38.9 ± 15.1              0.651
  Premorbid conditions (%)                    8 (42)           5 (42)                4 (57)                   0.650
  Initial radiographic findings (%)                                                                           0.813
   Normal                                     2 (11)           1 (8)                 1 (14)                   
   Focal opacity                              9 (47)           5 (42)                4 (57)                   
   Multifocal/diffuse opacity                 8 (42)           6 (50)                2 (29)                   
  Radiographic disease course (%)                                                                             0.048
   Type 1                                     2 (11)           0 (0)                 2 (29)                   
   Type 2                                     9 (47)           5 (42)                4 (57)                   
   Type 3                                     2 (11)           1 (8)                 1 (14)                   
   Type 4                                     6 (31)           6 (50)                0 (0)                    
  CT findings                                                                                                 
   Unilateral/bilateral (%)                   2 (11)/17 (89)   1 (8)/11 (92)         1 (14)/6 (86)            0.998
   Ground-glass opacity (%)                   19 (100)         12 (100)              7 (100)                  N/A
   Consolidation (%)                          14 (74)          10 (83)               4 (57)                   0.305
   Micronodules (%)                           3 (16)           2 (17)                1 (14)                   0.997
   Inter/intralobular septal thickening (%)   12 (63)          7 (58)                5 (71)                   0.656
   Pleural effusion (%)                       13 (68)          11 (92)               2 (29)                   0.010
   Number of the involved lobes               4.2 ± 1.4        4.2 ± 1.6             4.1 ± 1.2                0.973
  Total CT score                              9.2 ± 4.8        12.8 ± 4.5            6.4 ± 4.1                0.007

ARDS = acute respiratory distress syndrome, CT = computed tomography, N/A = not applicable
